These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. Enseleit F; Hürlimann D; Lüscher TF J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475 [TBL] [Abstract][Full Text] [Related]
48. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Panza JA; Casino PR; Badar DM; Quyyumi AA Circulation; 1993 May; 87(5):1475-81. PubMed ID: 8491002 [TBL] [Abstract][Full Text] [Related]
49. [The main determinants of endothelial dysfunction]. Garaliene V Medicina (Kaunas); 2006; 42(5):362-9. PubMed ID: 16778463 [TBL] [Abstract][Full Text] [Related]
50. The role of nitric oxide in bradykinin-induced dilation of coronary resistance vessels in patients with hypercholesterolemia. Kato M; Shiode N; Teragawa H; Hirao H; Yamada T; Yamagata T; Matsuura H; Kajiyama G Intern Med; 1999 May; 38(5):394-400. PubMed ID: 10397075 [TBL] [Abstract][Full Text] [Related]
51. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. Taddei S; Virdis A; Ghiadoni L; Salvetti A J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S37-40. PubMed ID: 10976779 [TBL] [Abstract][Full Text] [Related]
52. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Jamwal S; Sharma S Inflamm Res; 2018 May; 67(5):391-405. PubMed ID: 29372262 [TBL] [Abstract][Full Text] [Related]